Dr. Lanocha has more than 25 years of experience in neuromodulation therapies for treatment-resistant depression, including both TMS and ECT. He was among the first physicians in the country to begin offering TMS when it was approved by the FDA in 2008. He has lectured widely about TMS. His research activities have focused on long-term clinical outcomes following TMS treatment for major depression. Dr. Lanocha co-edited and contributed to “Transcranial Magnetic Stimulation: Clinical Applications for Psychiatric Practice,” which was published by the APA with key research findings on TMS.
Dr. Bermudes is Medical Director at TMS Health Solutions. He is the former president and a current board member of the Clinical TMS Society, a professional association dedicated to optimizing clinical practice, awareness, and affordability of Transcranial Magnetic Stimulation therapy. He has consulted with TMS industry leaders to help formulate insurance coverage policies for TMS therapy. He is editor of and contributor to “Transcranial Magnetic Stimulation: Clinical Applications for Psychiatric Practice”.
Dr. Cook is Director of the UCLA Depression Research and Clinic Program at the Semel Institute and Founding Chief of the TMS Treatment Service in the UCLA Department of Psychiatry. His research focuses on improving existing treatments for depression and developing new treatments for depression and related disorders. As both a biomedical engineer and a physician, he is at the forefront of the rapidly expanding field of neuromodulation and has published landmark studies of several novel neuromodulation therapies.
Paul E. Croarkin, DO, is focused on understanding the neurobiology, optimal treatment and classification of mood disorders in children and adolescents. This includes studies of repetitive transcranial magnetic stimulation (rTMS) for adolescent major depressive disorder; collaborative clinical trials; studies of neurophysiology with magnetic resonance spectroscopy (MRS); and novel, single and paired-pulse transcranial magnetic stimulation (TMS) paradigms.
A central theme among Dr. Croarkin's research is investigating the role of gamma-aminobutyric acid (GABA) and glutamate neurotransmitter systems in early-onset mood disorders with the goal of informing safer and more effective biologic treatments. He is on the faculty at the Mayo Clinic in Minnesota.
Dr. Demitrack has extensive experience in the treatment of mood disorders. His research has focused on using TMS for treatment-resistant depression. He has written extensively on the neuroendocrinology of mood disorders.
Dr Jonathan Downar serves as the Co-Director of the MRI-Guided rTMS Clinic at University Health Network, and also holds the position of Scientist at the Toronto Western Research Institute. He completed a BSc in biology at McGill University, followed by a PhD in neuroimaging at the University of Toronto with Dr. Karen Davis, before obtaining his medical degree from the University of Calgary in 2005. He then returned to Toronto for his psychiatry residency training, during which he also completed a research fellowship in neuroeconomics with Dr. Read Montague at Baylor College of Medicine.
Dr. Downar joined the Department of Psychiatry at UHN on completion of his residency in 2010. Shortly thereafter, he established the MRI-Guided rTMS Clinic. As of October, 2015, the clinic has received over 1600 community referrals and delivered over 20,000 sessions of stimulation.
Dr. Holtzheimer is the Director of the Mood Disorders Service at Dartmouth Hitchcock Medical Center, where his research is focused on the neurobiology and treatment of mood disorders, primarily treatment-resistant depression. He has been an investigator in several clinical trials of novel treatments, including TMS and deep brain stimulation, as well as numerous studies investigating the structural and functional neuroanatomy of mood disorders.
Previously at Rush University, Dr. Janicak is now Adjunct Professor of Psychiatry and Behavioral Sciences at Northwestern University and the Director of TMS at Linden Oaks. He has long been regarded as a leading expert in psychopharmacology and neuromodulation, including both TMS and ECT. He has written extensively on the long-term safety and efficacy of TMS in treatment resistant-depression, including the pivotal study leading to FDA approval of TMS. Dr. Janicack also co-edited and contributed to “Transcranial Magnetic Stimulation: Clinical Applications for Psychiatric Practice.”
Dr. Kuluva is Director of Neurology Services at TMS Health Solutions. He a board-certified neurologist and psychiatrist with a strong academic and research background. He treats patients with clinical depression and neurologic disorders. He sees individuals with neurologic disorders who experience psychiatric symptoms such as geriatric patients with cognitive issues, adults with developmental delays and behavior concerns, as well as depression. Dr. Kuluva also specializes in treating patients with traumatic brain injury and the post-concussive syndrome. Currently, he is running the TMS Memory Disorders Program and seeing excellent results.
Dr. Williams is an Instructor of Psychiatry at Stanford University, where his research program is focused on the development of new therapeutic approaches for treatment-resistant depression. He has been an investigator in several clinical trials of novel treatments, including intravenous ketamine and epidural cortical stimulation. Dr. Williams has been recently funded to complete several studies investigating the functional neuroanatomy of mood disorders with advanced imaging techniques. He is currently developing new forms of rTMS treatments such as accelerated theta-burst stimulation as well as biomarkers to measure the changes induced by rTMS such as resting-state functional connectivity MRI.